Tag Archives: Novartis

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release

What’s new in cancer care across Europe in early 2024 (1 Jan – 5 Mar 2024): Advancements, Innovations, Research, Awareness

(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release

Novartis Unveils Promising Results from SMART Study: Zolgensma’s Efficacy Confirmed in Older and Heavier SMA Patients

(IN BRIEF) Novartis has presented compelling data from the SMART study, reinforcing the clinical advantages of Zolgensma® (onasemnogene abeparvovec) in treating spinal muscular atrophy (SMA) patients weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 … Read the full press release

Novartis Outlines ‘Pure Play’ Innovative Medicines Strategy and Focused R&D Pipeline at London Event

(IN BRIEF) Novartis, a leading pharmaceutical company, presented its ‘pure play’ innovative medicines strategy and focused Research and Development (R&D) pipeline at an event in London. The company’s CEO, Vas Narasimhan, emphasized Novartis’ transformation into an innovative medicines-focused firm, highlighting … Read the full press release

Novartis Reports Positive Results for Atrasentan in IgA Nephropathy Study

(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release

Sandoz Group Lists Shares on SIX Swiss Exchange with CHF 10.3 Billion Market Capitalization

(IN BRIEF) Sandoz Group AG, a Novartis spin-off, officially listed its shares at the SIX Swiss Exchange. With an opening share price of CHF 24.00, the market capitalization of Sandoz reached approximately CHF 10.3 billion. Sandoz’s issued share capital consists … Read the full press release

Breakthrough: Lutathera Shows Significant Progress in Advanced Neuroendocrine Tumor Therapy

(IN BRIEF) Novartis has announced successful results from its Phase III NETTER-2 trial involving Lutathera, a treatment for neuroendocrine tumors (NETs). When used as a first-line treatment in combination with long-acting octreotide, Lutathera significantly improved progression-free survival in patients with … Read the full press release

Sandoz Gains Investment-Grade Rating Post Spin-off, Secures Substantial Financing

(IN BRIEF) Novartis has confirmed its plans for a full Spin-off of its Sandoz business, with trading of new Sandoz Group AG shares and ADRs scheduled to begin on October 4, 2023. This comes after receiving shareholder approval and key … Read the full press release

Novartis Reports Positive Phase III Outcomes for Novel Chronic Spontaneous Urticaria Drug

TOP-LINE DATA FROM REMIX-1 AND REMIX-2 STUDIES DEMONSTRATE SIGNIFICANT SYMPTOM IMPROVEMENT (IN BRIEF) Novartis has unveiled promising results from Phase III trials for remibrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, targeting chronic spontaneous urticaria (CSU). The REMIX-1 and REMIX-2 … Read the full press release

Deborah Dunsire to Retire as Lundbeck CEO, Charl van Zyl Named Successor

(IN BRIEF) H. Lundbeck A/S has announced the initiation of CEO succession, with Deborah Dunsire choosing to retire from her role as President and CEO. Charl van Zyl has been appointed as the new President and CEO, and Dunsire will … Read the full press release

Patients as Partners Europe Returns to London and Announces Agenda Highlights

(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will take place in London on June 12-13, 2023. The event will focus on achieving greater representation in clinical research, building … Read the full press release

Sandoz to Invest Over $400 Million in New Biologics Plant in Slovenia

(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has signed a Memorandum of Understanding to build a new biologics production plant in Lendava, Slovenia, in a move expected to be worth at least USD 400 million. The … Read the full press release

El CEO de Firmenich, Gilbert Ghostine, encabezará a Sandoz como presidente designado de la nueva junta directiva

(NOTICIA EN BREVE) Gilbert Ghostine ha sido designado presidente designado de la nueva junta directiva de Sandoz, tras el anuncio de la junta directiva de Novartis. La nueva Junta Directiva de Sandoz se formará en la segunda mitad de 2023, … Read the full press release

Firmenich CEO Gilbert Ghostine to Lead Sandoz as Chairman-Designate of New Board of Directors

(IN BRIEF) Gilbert Ghostine has been appointed as Chairman-designate of the new Board of Directors of Sandoz, following the announcement by Novartis Board of Directors. The new Board of Directors of Sandoz will be formed in the second half of … Read the full press release

La división Sandoz de Novartis amplía su cartera de medicamentos respiratorios con la adquisición de la empresa británica Coalesce Product Development Limited

Sandoz obtiene capacidades y activos significativos en el desarrollo de dispositivos médicos y medicamentos que apuntan a importantes oportunidades de crecimiento en genéricos complejos y respiratorios Las enfermedades respiratorias son la principal causa de muerte y discapacidad e imponen una … Read the full press release

Novartis division Sandoz expands respiratory medicines portfolio with the acquisition of British company Coalesce Product Development Limited

Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide Acquisition … Read the full press release

Patients and R&D Leaders Jointly Present at EU Conference on Progress with Patient-Input to Transform Medicine Development

(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. ​​This … Read the full press release

Paul Bestford to lead Nutreco’s procurement

(PRESS RELEASE) AMERSFOORT, 13-Sep-2021 — /EuropaWire/ — Nutreco, a global leader in animal nutrition and aquafeed, has announced the appointment of Paul Bestford as the company’s new Chief Procurement Officer (CPO). Paul is coming from Burberry where he led the … Read the full press release

Novartis welcomes new Chief Legal Officer Karen L. Hale

(PRESS RELEASE) BASEL, 22-Mar-2021 — /EuropaWire/ — Swiss multinational pharmaceutical Novartis appoints Karen L. Hale as Chief Legal Officer. She succeeds Shannon Klinger. Karen will be based in Basel, Switzerland and will join the Executive Committee of Novartis (ECN) and … Read the full press release

Genetic diversity: GSK and Novartis launch Project Africa GRADIENT to optimise treatment responses for malaria and tuberculosis in Africa

Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients. Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years. Researchers … Read the full press release

Novartis signs 10 year 78 MW renewable Virtual Power Purchase Agreement (VPPA) with Enel Green Power

The energy will be generated by the 179.9 MW TICO Wind Farm, located in the Spanish province of Zaragoza, Enel Green Power will be a “Green Enabler” for Novartis, supporting the company along its environmental sustainability journey (PRESS RELEASE) ROME, … Read the full press release

Wet Macular Degeneration: Promising data for Novartis’ Beovu unveiled at EURETINA

In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment1 Patients with early persistent fluid treated with Beovu experienced greater … Read the full press release

Deutsche Bank part of major initiative aimed at creating a common basis for sustainability to be accepted by capital markets

The initiative aims at transforming the way companies are valued (PRESS RELEASE) FRANKFURT AM MAIN, 22-Aug-2019 — /EuropaWire/ — Deutsche Bank has announced it is joining the value balancing alliance e.V.. Established as a non-profit organization the alliance was founded … Read the full press release

Francesco Balestrieri appointed ad-interim CEO of Sandoz reporting directly to Vas Narasimhan, CEO, Novartis

(PRESS RELEASE) BASEL, 15-Mar-2019 — /EuropaWire/ — Sandoz’s current Region Head Europe Francesco Balestrieri has just been appointed ad-interim CEO of Sandoz reporting directly to Vas Narasimhan, CEO, Novartis. The change is made as the current CEO of Sandoz, a … Read the full press release

Novartis and Pfizer announce clinical development agreement for the treatment of NASH

Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has a leading development portfolio in non-viral liver diseases, including NASH There are currently no … Read the full press release

Novartis announces EC approval for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for adjuvant treatment of BRAF V600 mutation-positive melanoma

Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients   More than 50% of stage III melanoma patients are likely to recur to stage IV during their lifetime … Read the full press release

Novartis: European Commission approval for Kymriah

The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r pediatric B-cell ALL and r/rDLBCL Novartis is the only company with an approved … Read the full press release

Novartis: the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 has met the primary endpoint

SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase inhibitor with or without a CDK4/6 inhibitor[1] Approximately 40% of HR+ advanced breast cancer … Read the full press release

Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke

Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally[1] Since the start of the donation program in … Read the full press release

Novartis’ Alcon AcrySof IQ PanOptix intraocular lens unveils new data showing significantly improved near and intermediate distance vision

Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1]  Detailed findings presented at World Ophthalmology Congress 2018 Recent survey reveals 82% of people 60+ are willing to have advanced surgical options … Read the full press release

GlaxoSmithKline plc completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion

Brentford, UK, 05-Jun-2018 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*). The transaction, which was previously announced on 27 … Read the full press release

Sandoz announces European Commission approval for Zessly® (infliximab) for use in Europe

European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems Zessly is the third EC … Read the full press release

Novartis division Sandoz receives US FDA complete response letter regarding the Biologics Licensing Application for its proposed biosimilar rituximab

Holzkirchen, Germany, 04-May-2018 — /EuropaWire/ — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab. Sandoz stands behind … Read the full press release

Novartis: Today’s FDA approval of Kymriah provides another opportunity for Novartis to build on its leadership in CAR-T development

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only CAR-T therapy FDA-approved for two distinct indications – in non-Hodgkin … Read the full press release

Novartis, Pear Therapeutics to work together towards developing new treatments for patients with schizophrenia and multiple sclerosis

Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis’ leadership in biomedical research and clinical development with Pear’s expertise in digital therapeutics  Novartis continues to embrace emerging … Read the full press release

Novartis: US FDA grants Breakthrough Therapy designation to Promacta® (eltrombopag) for the treatment of patients with SAA

Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%[1] Promacta is the only TPO receptor agonist indicated for the treatment of patients … Read the full press release

Novartis: positive topline results from the global MONALEESA-7 trial

MONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal women with HR+/HER2- advanced breast cancer[1]  Kisqali is the first CDK4/6 inhibitor to be studied in a Phase … Read the full press release

Novartis announced results from the FUTURE 5 study on psoriatic arthritis (PsA)

Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced mobility and irreversible joint damage[2]     FUTURE 5 is the largest randomized controlled … Read the full press release

Novartis: ACZ885 led to 15% reduction in the risk of major adverse cardiovascular events (MACE) compared to placebo

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy Effect driven … Read the full press release

Novartis: ACZ885 reduced the rate of lung cancer incidence and mortality among study participants

Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a … Read the full press release